Phase I/II Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies.
Phase of Trial: Phase I/II
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Dasatinib (Primary)
- Indications Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 13 Jul 2016 Planned End Date changed from 1 Aug 2015 to 1 Aug 2018.
- 13 Jul 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2018.
- 13 Jul 2016 Status changed from active, no longer recruiting to recruiting.